People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality ...

This update to the NICE HealthTech programme manual sets out in greater detail methods to be used by the NICE HealthTech programme when developing HealthTech guidance. This includes approaches for ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) is available on the NHS as a possible treatment for cystic fibrosis. It is for people 6 years and over who have at least 1 F508del mutation in the ...

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] ...

REGN5458 for treating relapsed or refractory multiple myeloma [ID6609] Awaiting development GID-TA11810 Expected publication date: TBC ...

Suggested remit: To appraise the clinical and cost effectiveness of olezarsen within its marketing authorisation for treating familial chylomicronaemia syndrome. Key events during the development of ...

The recorded number of people referred to access NHS Talking Therapy services in 2023 to 2024 was 1.26 million (NHS Digital). Of this group, 672,000 people referred completed a course of treatment.

5 Minimum evidence standards There is some clinical evidence that suggests that the digital front door technologies support the pre-assessment process for accessing Talking Therapies services, and ...

1 Purpose of this document NICE's early value assessment guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments ...